Article By:
Fredrik Arnold
Tuesday, July 19, 2022 3:00 AM EDT
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. It was founded in 1973 and is headquartered in Paris.
In this article: SNY
There Is Beta In Protalix Stock Due To PRX-102
Isn't that made by Sanofi $SNY?
Protalix BioTherapeutics Pipeline Progress
#Protalix clearly has a lot of potential but there's a limited number of people who will need this drug. So the real question is how much of a dent will they put into #Sanofi's market share. $PLX $SNY
Protalix BioTherapeutics Pipeline Progress
My pleasure. What's more important than how prevalent the disease is, is how much money #Protalix can make on its new drug. It's competitor, #Sanofi ($SNY) makes $1 billion in revenue annually on their drug. Protalix's sounds like a more promising alternative. I'd definitely rate $PLX a buy.